Chardan Capital restated their buy rating on shares of Medivation (NASDAQ:MDVN) in a report issued on Monday, American Banking & Market News reports. They currently have a $72.00 target price on the stock.
Medivation (NASDAQ:MDVN) traded down 4.77% on Monday, hitting $60.85. 1,195,033 shares of the company’s stock traded hands. Medivation has a 52-week low of $41.89 and a 52-week high of $59.86. The stock’s 50-day moving average is $57.49 and its 200-day moving average is $52.09. The company’s market cap is $4.577 billion.
Medivation (NASDAQ:MDVN) last announced its earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.14. The company had revenue of $70.15 million for the quarter, compared to the consensus estimate of $59.35 million. During the same quarter in the previous year, the company posted ($0.15) earnings per share. The company’s revenue for the quarter was up 63.5% on a year-over-year basis. Analysts expect that Medivation will post $-0.90 EPS for the current fiscal year.
In other Medivation news, Insider Cheryl Cohen sold 50,000 shares of Medivation stock on the open market in a transaction dated Thursday, October 24th. The stock was sold at an average price of $64.25, for a total transaction of $3,212,500.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
A number of other firms have also recently commented on MDVN. Analysts at Maxim Group raised their price target on shares of Medivation from $66.00 to $71.00 in a research note to investors on Monday. They now have a buy rating on the stock. Separately, analysts at Aegis reiterated a buy rating on shares of Medivation in a research note to investors on Tuesday, October 22nd. Finally, analysts at Zacks downgraded shares of Medivation from an outperform rating to a neutral rating in a research note to investors on Wednesday, August 28th. They now have a $59.00 price target on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. Medivation has an average rating of Buy and a consensus target price of $66.17.
Medivation, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.